Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 10/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLG | P54098 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763085 | 1.00 | NT5E (0.64) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL3789915 | 1.00 | NT5E (0.64) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL1763054 | 0.92 | NT5E (0.60) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL1762790 | 0.92 | NT5E (0.60) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL3414689 | 0.90 | NT5E (0.58) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL1763028 | 0.90 | NT5E (0.58) | NT5ELMNATHRBMTORMDM2 | |
| Ammonia Solution, Strong SCHEMBL1763145 | 0.89 | NT5E (0.57) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL3926895 | 0.89 | NT5E (0.61) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL380557 | 0.88 | NT5E (0.60) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL4650289 | 0.85 | NT5E (0.57) | NT5ELMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4542021-A | 1-B-D-ARABINOFURANOSYLCYTOSINE-5'-PHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1985-09-17 | — | — | US | claimed |
| JP-55129299-A | — | — | None | — | — | JP | disclosed |
| JP-59048498-A | — | — | None | — | — | JP | disclosed |
| US-20160095932-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | MBC PHARMA, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9216204-B2 | Bone targeted therapeutics and methods of making and using the same | MBC PHARMA, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140051625-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | MBC PHARMA, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8614312-B2 | Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-8586781-B2 | Bone targeted therapeutics and methods of making and using the same | MBC PHARMA, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-2265624-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
| US-7598246-B2 | Bisphosphonate conjugates and methods of making and using the same | MBC PHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2009115694-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-09-24 | — | — | WO | disclosed |
| US-20090227544-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | MBC PHARMA, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20050026864-A1 | Bisphosphonate conjugates and methods of making and using the same | MBC PHARMA, INC. | 2005-02-03 | — | — | US | disclosed |
| US-4542021-A | 1-B-D-ARABINOFURANOSYLCYTOSINE-5'-PHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1985-09-17 | — | — | US | disclosed |
| US-4542021-A | 1-B-D-ARABINOFURANOSYLCYTOSINE-5'-PHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1985-09-17 | — | — | US | disclosed |
| JP-S5948498-A | 1-BETA-D-ARABINOFURANOSYLCYTOSINE-5'-PHOSPHORIC ACID DERIVATIVE | YAMASA SHOYU CO LTD | 1984-03-19 | — | — | JP | disclosed |
| JP-S55129299-A | 1-BETA-D-ARABINOFURANOSYL-CYTOSINE-5'-PHOSPHORIC ALKYL ESTER | YAMASA SHOYU CO LTD | 1980-10-06 | — | — | JP | disclosed |
| US-4086417-A | ANTILEUKEMIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051625-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | SOST, BPGM, BST2 | NT5E 230/4885LMNA 3715/4885THRB 897/4885 |
| US-20050026864-A1 | Bisphosphonate conjugates and methods of making and using the same | BPGM, SOST, ENPP2 | NT5E 251/4885LMNA 3292/4885THRB 838/4885 |
| US-20090227544-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | SOST, BPGM, BST2 | NT5E 230/4885LMNA 3715/4885THRB 897/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | NT5E 50/4885LMNA 625/4885THRB 3758/4885 |
| US-20160095932-A1 | Bone Targeted Therapeutics and Methods of Making and Using the Same | SOST, BPGM, BST2 | NT5E 230/4885LMNA 3715/4885THRB 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.